St. Jude Children’s Research Hospital scientists have demonstrated that the long-term performance of cancer-killing chimeric antigen receptor (CAR) T cells can, in some cases, be predicted before treatment.
| Scientists at St. Jude Children’s Research Hospital have developed a method that may be able to improve CAR T-cell therapies by identifying the early cells that become effective at killing cancer. MEMPHIS, Tenn., July 6, 2022 /PRNewswire/ -- St. Jude Children’s Research Hospital scientists have demonstrated that the long-term performance of cancer-killing chimeric antigen receptor (CAR) T cells can, in some cases, be predicted before treatment. The research provides a unique cell sequencing-based framework to measure and improve CAR T–cell immunotherapy performance. The report appears online early today in Cancer Discovery, a journal of the American Association for Cancer Research.
St. Jude scientists develop a method to identify early cells that effectively kill cancer in CAR T-cell therapy CAR T cells work by harnessing a patient’s immune system to identify and kill cancer cells. The immunotherapy has proven effective for treating children and adults with leukemia and lymphoma, but the therapy sometimes fails or falters over time. Using advanced technologies in the lab, St. Jude researchers identified a small subset of CAR T cells, among the total group of CAR T cells prepared for therapy, produced most of the enduring anti-cancer activity when infused into children with acute lymphoblastic leukemia (ALL). The methodological framework the scientists created serves as a template to improve other CAR T–cell therapies by providing a guide to navigate the complexities of these immunotherapies. “It was a surprising finding,” said co-corresponding author Paul Thomas, Ph.D., St. Jude Department of Immunology. “It appears that a very small proportion, certainly the minority of CAR positive T cells in the pre-infusion product, are actually contributing to the anti-tumor response in the patient.” Before the study, researchers assumed most CAR T cells created in a single preparation are similar, with cancer clearance activity representing the average activity of those prepared cells. “We showed that, in this case, a small group of cells is the driving force of cancer clearance,” said co-corresponding author Jeremy Chase Crawford, Ph.D., St. Jude Department of Immunology. “The ability to find the therapy-driving cells was important to demonstrate because in the future a refined version of this method could be used to identify and enrich for infused cells that are going to be helpful to a patient, as opposed to cells that aren’t.” A signature of potential success The scientists found a distinct gene expression “signature” in the pre-infusion CAR T cells that became effector T cells, the type of immune cell that killed cancer cells. The team found three genes within that signature that encoded proteins expressed on the T–cell surface. Cells that carried a particular combination of the surface proteins became effector T cells; the other CAR T cells became dysfunctional. The technology to sort cells by surface markers exists and could be used to enrich CAR T–cell preparations to include only cells fated to become effective cancer killers. The researchers clarified that the cell surface markers identified in this study may be unique to this combination of CAR T cell, ALL and patient population. But the method the researchers pioneered serves as a proof-of-principle of how other CAR T–cell therapies could be improved. To find the signature, researchers collected CAR T cells in the laboratory before they were given to patients (pre-infusion). The investigators later collected blood samples from the patients, weeks and months into the study. They were able to track the fate of the infused CAR T cells using single-cell RNA sequencing. “Right now,” Thomas said, “almost everything for CAR products is assessed at a bulk level. We showed that you need to look at the single-cell level to define the phenotypes of those cells that are going to be the critical effectors in the patient.” A barcode to identify CAR T-cell descendants The researchers’ novel approach combines a T-cell “barcode” with single-cell gene expression sequencing in pediatric cancer patients. This allows them to follow T–cell lineages. Each original T–cell lineage taken from the patient has a unique protein, called the T–cell receptor (TCR). In a patient, an activated CAR T cell will divide and proliferate after encountering cancer cells. So, every T cell from a patient with an identical TCR is descended from the same original T–cell lineage, which was modified in the laboratory prior to infusion. Thus, the TCR can act as a barcode for a specific lineage of CAR T cells. The scientists sequenced the TCRs in the pre-infusion cells and in patient samples after therapy. Using machine learning, the researchers compared genetic transcripts from single cell sequencing to see if cells became effectors. From this tracing, the investigators found that a small proportion of pre-infusion cells, specifically those with the pre-effector signature, become effectors and proliferate in the patient. The first of its kind study was made possible due to a cross-departmental collaborative effort at St. Jude aimed at integrating clinical trials and basic immunological research, called the Center for Translational Immunology and Immunotherapy (CeTI2). Scientist obtained samples from a clinical trial called SJCAR19, the first investigator-initiated CAR T–cell therapy study at St. Jude, led by study co-author Aimee Talleur, MD, St. Jude Department of Bone Marrow Transplantation and Cellular Therapy. “The study illustrates a huge team effort and brought together investigators from basic science and the clinic,” said co-corresponding author Stephen Gottschalk, M.D., St. Jude Department of Bone Marrow Transplantation and Cellular Therapy chair, “It highlights the virtue of team science and the promise of single-cell technologies combined with big data analytics to develop effective cellular immunotherapies for cancer.” Authors and funding The study’s co-first authors are Taylor Wilson of St. Jude, and Hyunjin Kim, formerly of St. Jude. The other authors are Ching-Heng Chou, formerly of St. Jude, Deanna Langfitt, Robert Mettelman, Anastasia Minervina, E. Kaitlynn Allen, Jean-Yves Métais, Mikhail Pogorelyy, Janice Riberdy, M. Paulina Velasquez, Pratibha Kottapalli, Sanchit Trivedi, Scott Olsen, Timothy Lockey, Catherine Willis, Michael Meagher and Brandon Triplett, all of St. Jude. The study was supported by grants from by the National Cancer Institute (P30CA021765); the National Institutes of Health (U01AI150747 and R01AI136514); the American Society of Transplantation and Cellular Therapy; the American Society of Hematology; the Key for a Cure Foundation; the Mark Foundation ASPIRE Award; NRSA-NIAID (F32AI157296) and ALSAC, the fundraising and awareness organization of St. Jude. St. Jude Children’s Research Hospital St. Jude Children’s Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 60 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.
SOURCE St. Jude Children’s Research Hospital |
View original content to download multimedia: